Search

Displaying results 1761 - 1770 of 6076 in total
  1. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A196128] Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).[L16343] … Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.

  4. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.

  5. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  6. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44186] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended etranacogene dezaparvovec be granted marketing authorization for the treatment of severe and moderately … [L44161,L44181] Etranacogene dezaparvovec (Hemgenix, CSL Bering LLC) is a gene therapy for the treatment of hemophilia B that provides a new treatment modality for its patients.

  7. Drug

    Nitrite

    go.drugbank.com/drugs/DB12529
    ApprovedWithdrawn

    Nitrite is under investigation for the treatment of Heart Failure.

  8. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). … Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting

  9. Drug

    Dengue virus serotype 4

    go.drugbank.com/drugs/DB22667
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  10. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for